NewGenIvf Group Stock Price, News & Analysis

NewGen IVF Group (NASDAQ: NIVF) has announced that its subsidiary, First Fertility PGS Center, is launching specialized fertility services targeting Indian medical tourists in Thailand. The initiative includes a dedicated Indian hospitality lounge, Hindi-speaking staff, and comprehensive fertility treatments including family balance through IVF. This expansion aims to capitalize on Thailand's growing fertility tourism sector, leveraging the country's world-class medical infrastructure and visa-free entry for Indian nationals.

The strategic move aligns with significant market growth projections, as the global fertility tourism market is expected to grow from US$709 million in 2023 to US$13.08 billion by 2034, representing a 30.34% CAGR. The company's services are specifically designed to address the unique cultural and medical needs of Indian patients, offering treatments that may be restricted in their home country.

NewGenIVF Group Limited (NASDAQ: NIVF), an Asian fertility services provider, has announced a 1-for-10 reverse stock split effective May 5, 2025. The reverse split will reduce outstanding Class A Ordinary Shares from 7,302,819 to approximately 730,282 shares. The company will continue trading under the symbol "NIVF" on the Nasdaq Global Market with a new CUSIP number G0544E121.

No fractional shares will be issued - shareholders entitled to fractional shares will receive one full post-split share instead. All outstanding options, warrants, and convertible securities will be proportionally adjusted by dividing the number of shares by ten, subject to rounding to the nearest whole share.

NewGen IVF Group (NASDAQ: NIVF), an Asian fertility services provider, has filed its 2024 annual report on Form 20-F with the SEC on April 22, 2025. The company reported $2.48 million in cash and a $1 million cash deposit with a trading platform, which exceeds their current market capitalization of $1.48 million.

The company has improved its financial position by settling outstanding promissory notes and converting mandatory additional notes to equity. NewGen maintains access to a $100 million equity line of credit facility, of which $7.1 million has been utilized.

NewGen (NASDAQ: NIVF) has secured $5.2 million in strategic funding through two arrangements, with potential to raise up to $30.8 million total. The funding includes a $2 million senior convertible note with 14.75% annual interest rate and a new agreement for up to $3.2 million, with possibility for additional notes up to $25.6 million.

The capital will primarily fund the establishment of a state-of-the-art fertility clinic in Dubai, UAE, leveraging NewGen's exclusive Microsort technology. The Dubai facility will offer comprehensive fertility services including IVF with gender selection, egg donation, and surrogacy, targeting patients from UAE, European Union, and neighboring regions, particularly India.

Construction is scheduled to begin in Q2 2025, with facility opening targeted for Q4 2025. The expansion capitalizes on Dubai's position as a global travel hub and the UAE's progressive fertility treatment regulatory framework.

NewGenIvf Group (NASDAQ: NIVF) has announced the termination of its previously announced reverse merger transaction with European Wellness Investment Holdings (EWIHL). The merger, announced on December 11, 2024, would have given EWIHL approximately 61.6% equity in NewGen.

The termination occurred because EWIHL failed to deliver required draft audited financial statements for 2023 and 2024 by the March 31, 2025 deadline. Per the binding term sheet terms, NewGen exercised its right to terminate the transaction at no cost.

Despite this development, NewGen's CEO Siu Wing Fung Alfred expressed confidence in the company's future, highlighting growth opportunities in existing business lines, including their recent Microsort acquisition and lifetime egg-freezing service. The company remains open to strategic alternatives aligned with their long-term objectives.

NewGenIvf Group (NASDAQ: NIVF) provided updates on two significant corporate developments. First, regarding its proposed reverse merger with European Wellness Investment Holdings (EWIHL), which would give EWIHL 61.6% equity stake, key conditions remain unmet including delivery of draft audited financials for 2023-2024 by March 31, 2025. If these conditions aren't met by the deadline, NewGen will terminate the term sheet at no cost.

Second, the company confirmed completion of its MicroSort Reproductive Technology acquisition on February 28, 2025. Notably, NewGen has improved its financial position, transforming from a $7 million deficit to a $10 million surplus between September 2024 and February 2025, achieving a $17 million net asset increase. The company reports a net asset value per share of $2.16 and only $50,000 in debt as of February 2025.

NewGenIvf Group (NASDAQ: NIVF) has announced a strategic collaboration with BOBCARE FERTILITY GROUP to expand fertility services in Kyrgyzstan. The partnership combines NewGen's technical expertise in fertility treatments with BOBCARE's regional market resources.

The collaboration includes several key initiatives:

• Enhancement of clinical protocols and patient management systems
• Knowledge exchange between fertility specialists
• Coordinated marketing and brand-building activities
• Development of specialized fertility treatments for the regional market

The partnership aligns with the China-Kyrgyzstan economic cooperation under the 'One-Belt-One-Road' framework. Kyrgyzstan represents a developing market for fertility services in Central Asia, characterized by a young population and evolving perspectives on fertility treatments.

NewGenIvf Group (NIVF) has successfully regained compliance with Nasdaq's minimum bid price requirement, as announced on February 27, 2025. The company had previously received a non-compliance notice on October 8, 2024, when its Class A Ordinary Shares traded below $1.00 for 30 consecutive business days.

The compliance was achieved after the company's shares maintained a closing bid price of $1.00 or higher for 10 consecutive business days from February 11-26, 2025. Additionally, NIVF received approval to transfer its listing from the Nasdaq Global Market to the Nasdaq Capital Market, effective February 28, 2025. The company's ordinary shares and warrants will continue trading under the symbols 'NIVF' and 'NIVFW' respectively, with no expected impact on securities trading.

NewGen (NASDAQ: NIVF) issued a clarification regarding its February 20, 2025 press release about Nasdaq listing compliance. The company clarified it has not yet achieved compliance with Nasdaq's $2.5 million minimum stockholders' equity requirement. However, during Q1, $2.3 million of debt was converted to equity, and approximately $4.3 million was drawn from its Equity Line of Credit with White Lion Capital.

The company believes it currently exceeds the $2.5 million stockholders' equity requirement but awaits Nasdaq confirmation. The Nasdaq Hearings Panel has granted NewGen an extension to meet compliance requirements. As part of its compliance plan, the company completed a reverse split on February 11, 2025, and has maintained a closing bid price above $1.00 for six consecutive trading days as of February 19, 2025. NewGen plans to apply for transition to the Nasdaq Capital Market by February 26, 2025.